Inclisiran: A Jab Goes a Long Way

High levels of low-density lipoprotein (LDL) cholesterol can increase the risk of atherosclerosis and cardiovascular events such as a heart attack or stroke. Inclisiran, now approved by NICE (2021) can be used to reduce LDL cholesterol.

Do you know when, how and on which patients to use the novel anti-cholesterol drug inclisiran to treat elevated LDL in patients with hypercholesterolaemia, mixed dyslipidaemia or patients that have had a previous cardiovascular event?

Join our webinar and learn more during an interactive panel discussion, showcasing real-world case applications of this new agent, produced as part of the ISCP series on the A to Z of CV Pharmacotherapy.

• To evaluate and understand which patients should and should not receive inclisiran and which patients groups might benefit most
• To determine how inclisiran should be administered and what dosage adjustments, drug interactions or pharmacogenetic issues need to be noted
• To analyse special and regional issues that impact the use of this agent and evaluate which groups will benefit most
  To apply evidence-based recommendations to two real world cases

• Cardiovascular team members – doctors, nurses and pharmacists
• Family physicians
• Internists
• Cardiovascular pharmacotherapy researchers

Led by moderators Dr Krittin Bunditakanul (Bangkok, Thailand) and Dr Doreen Tan (Singapore), the webinar includes a speaker presentation from Prof Kyzysztof Filipiak (Warsaw, Poland), two case presentations from Dr Bundaitakanul and discussions from panellists Prof Bernard Cheung (Hong Kong) and Dr Alberto Lorenzatti (Argentina) that will examine the considerations for use of this new agent, through interesting real-world examples, live discussions and audience Q&A.